ICEPAC: A phase II multicenter study of avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC).
Arun Azad, Lavinia Anne Spain, Angelyn Anton, Chun Loo Gan, Linda Garrett, Deborah Chang, Caitlin Bennett, Gargi Kothari, Mark Shaw, Phillip Parente, Carmel Jo Pezaro, Ben Tran, Shankar Siva, Edmond Michael Kwan
Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2021
86 Background: Studies investigating immune checkpoint inhibitors (ICI) in mCRPC have produced modest results. Radiation therapy may be synergistic with ICIs. We hypothesised that SABR would enhance anti-tumour activity of PD-L1 inhibitor avelumab in patients (pts) with progressive mCRPC. Methods: This phase II, single arm, multicentre study enrolled mCRPC pts following progression on ≥1 novel androgen receptor-directed therapy. Up to two lines of prior taxane chemotherapy were permitted. Pts received avelumab 10mg/kg IV q2weeks for a total of 24 weeks (12 cycles). A single fraction of 20Gy SABR was administered to 1-2 disease sites within five days prior to first and second doses of avelum..View full abstract